OKYO Pharma Ltd ADR (OKYO) Peer Comparison
$1.54
$-0.01
(-0.65%)
As on 27-Aug-2026 13:06EDT
Market cap
$81 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
6.4
Div. Yield
0 %
Edit
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
81 | 2,920 | 1,862 | 914 | 839 |
Revenue ($ Mln) |
-- | 450 | 1,044 | -- | 366 |
Net Profit ($ Mln) |
-8.95 | -188.21 | 488.78 | -175.85 | 9.27 |
Net Margin (%) |
-- | -41.86 | 46.83 | -- | 2.53 |
RoE (%) |
-263.80 | -28.46 | 15.95 | -106.84 | 3.39 |
Price to Earnings |
-- | -- | 3.18 | -- | 84.64 |
Price-To-Book |
6.38 | 4.82 | 0.49 | 5.59 | 3.06 |
Income Statement ($ Mln)
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | -- | -- | -- | -- |
|
Cost of Revenue
|
6.69 | -- | -- | -- | -- |
|
Gross Profit
|
-6.69 | -- | -- | -- | -- |
|
Operating Expenses
|
1.81 | -- | -- | -- | -- |
|
Operating Profit (EBIT)
|
-8.50 | -- | -- | -- | -- |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-8.94 | -- | -- | -- | -- |
|
Provision for Tax
|
0.01 | -- | -- | -- | -- |
|
Profit after Tax (Net Income)
|
-8.95 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
12.34 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.00 | -- | -- | -- | -- |
|
Current Liabilities
|
8.64 | -- | -- | -- | -- |
|
Total Liabilities
|
20.98 | -- | -- | -- | -- |
Assets ($ Mln)
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.01 | -- | -- | -- | -- |
|
Current Assets
|
20.97 | -- | -- | -- | -- |
|
Total Assets
|
20.98 | -- | -- | -- | -- |
|
Total Debt*
|
-- | -- | -- | -- | -- |
|
Net Current Assets
|
12.33 | -- | -- | -- | -- |
Cashflow ($ Mln)
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-5.94 | -- | -- | -- | -- |
|
Cash Flow from Investing Activities
|
-6.01 | -- | -- | -- | -- |
|
Cash from Financing Activities
|
25.02 | -- | -- | -- | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-263.80 | -- | -- | -- | -- |
|
ROE (%)
|
-263.80 | -- | -- | -- | -- |
|
ROA (%)
|
-72.60 | -- | -- | -- | -- |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -- | -- | -- | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -- | -- | -- | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-90.16 | -- | -- | -- | -- |
|
EPS Growth (%)
|
-1.01 | -- | -- | -- | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-6.73 | -- | -- | -- | -- |
|
Price / Book Value
|
4.88 | -- | -- | -- | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-4.68 | -- | -- | -- | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-- | -- | -- | -- | -- |
|
Short term debt to equity ratio
|
-- | -- | -- | -- | -- |
|
Current Ratio
|
2.43 | -- | -- | -- | -- |
|
Quick Ratio
|
-- | -- | -- | -- | -- |
|
Interest Coverage
|
-17.87 | -- | -- | -- | -- |
Operating Efficiency Ratios
| OKYO Pharma Ltd ADR (OKYO) | Zai Lab - ADR | Galapagos NV - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | -- | -- | -- | -- |
|
Asset Turnover
|
0.00 | -- | -- | -- | -- |
|
Receivable days
|
-- | -- | -- | -- | -- |
|
Inventory Days
|
-- | -- | -- | -- | -- |
|
Payable days
|
410.43 | -- | -- | -- | -- |
|
Cash Conversion Cycle
|
-- | -- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
